# 基于纳米技术的药物递送市场

> 基于纳米技术的药物递送市场研究报告，按应用（癌症治疗、心血管疾病、神经系统疾病、传染病、自身免疫疾病）、按纳米颗粒类型（脂质体、高分子纳米颗粒、树枝状聚合物、固体脂质纳米颗粒、纳米晶体）、按给药途径（静脉注射、口服、局部、吸入、经皮）、按最终用途（医院、制药公司、研究机构、居家护理）以及按地区（北美、欧洲、南美、亚太、中东和非洲） - 预测到2035年

- **Forecast Period:** 2025 - 2035
- **CAGR:** 10.72%
- **2024:** $ 7.37 Billion
- **2025:** $ 8.16 Billion
- **2035:** $ 22.59 Billion
- **Key Players:** Companies such as Amgen (US), Bristol-Myers Squibb (US), Johnson & Johnson (US), Roche (CH), Novartis (CH), Pfizer(US), Merck & Co. (US), Sanofi (FR), AstraZeneca (GB) are some of the major participants in the global market.

**Report ID:** MRFR/HC/32172-HCR · **Pages:** 100 · **Author:** Rahul Gotadki · **Last Updated:** May 18, 2026

**URL:** https://www.marketresearchfuture.com/reports/nanotechnology-based-drug-delivery-market-34011

---

## Market Summary

## **Nanotechnology-Based Drug Delivery Market Overview**

As per MRFR analysis, the Nanotechnology-Based Drug Delivery Market Size was estimated at 7.37 (USD Billion) in 2024. The Nanotechnology-Based Drug Delivery Market Industry is expected to grow from 8.16 (USD Billion) in 2025 to 20.41 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 10.72% during the forecast period (2025 - 2034).

### **Key Nanotechnology-Based Drug Delivery Market Trends Highlighted**

The Nanotechnology-Based Drug Delivery Market is experiencing significant growth driven by increasing demand for targeted therapies and personalized medicine. Advancements in nanotechnology are enabling more effective drug delivery systems that enhance therapeutic efficacy while minimizing side effects.

The rising prevalence of chronic diseases such as cancer and diabetes fuels the need for innovative treatment options, which further propels market expansion. Additionally, investments in research and development by pharmaceutical companies to explore nanoparticle formulations and improve bioavailability are central to leveraging growth opportunities.

Recent times have shown a growing focus on the integration of nanotechnology with other therapeutic modalities, such as immunotherapy and gene therapy. This trend highlights the potential for multifunctional drug delivery systems that can address complex health issues more effectively.

Moreover, regulatory agencies are becoming more supportive of nanotechnology applications in medicine, paving the way for faster approvals and market access. The shift towards tailored therapies is also leading to an increased emphasis on compatibility with existing drugs, enabling a more streamlined approach to treatment options. 

In exploring opportunities within this market, stakeholders can focus on untapped regions and niches, particularly in emerging economies where healthcare advancements are rapidly evolving.

Collaboration between academia and industry can foster innovation, leading to novel drug delivery solutions that cater to unmet medical needs. As the market continues to mature, a holistic approach involving interdisciplinary research and strategic partnerships will be vital in maintaining momentum and achieving long-term success in the nanotechnology-based drug delivery landscape.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Nanotechnology-Based Drug Delivery Market Drivers**

### Increasing Demand for Targeted Drug Delivery Systems

The Nanotechnology-Based Drug Delivery Market Industry is experiencing significant growth due to the increasing demand for targeted drug delivery systems. Traditional drug delivery methods often cause systemic side effects, and patients are increasingly seeking more efficient alternatives that can deliver medication directly to the site of action.

Nanotechnology enables the development of drug carriers that can encapsulate therapeutic agents and release them in a controlled manner, improving the efficacy of treatment while minimizing adverse effects.As personalized medicine continues to evolve, there is a heightened need for innovative solutions that nanotechnology provides. 

This technology offers the capability to tailor treatment to individual patients based on their unique biological responses, thereby increasing patient compliance and satisfaction. Furthermore, advancements in nanomaterials have led to the creation of nanoparticles that can overcome biological barriers and enhance the solubility and stability of drugs.These factors collectively drive the demand for nanotechnology-based drug delivery systems, making it one of the key market drivers in the industry.

### Advances in Nanotechnology Research and Development

Research and development efforts in nanotechnology have made substantial advancements, propelling the Nanotechnology-Based Drug Delivery Market Industry forward. With ongoing studies focusing on nanomaterials and their interaction with biological systems, new and efficient drug delivery methods are being discovered. These innovations not only enhance the therapeutic effects of existing drugs but also lead to the creation of new formulations tailored for specific diseases.

The collaboration between academic institutions and industry players has resulted in a rich pipeline of products that integrate cutting-edge nanotechnology applications. This dynamic research environment fosters continuous improvement and adaptation within the market, further fueling its growth and responding to evolving healthcare needs.

### Rising Prevalence of Chronic Diseases

The increase in the prevalence of chronic diseases such as cancer, diabetes, and cardiovascular disorders is significantly driving the Nanotechnology-Based Drug Delivery Market Industry. Chronic illnesses often require long-term treatment regimens that benefit from more effective drug delivery systems. The ability of nanotechnology to improve drug bioavailability and provide sustained release mechanisms is invaluable in managing such conditions.

Additionally, the aging population worldwide is contributing to the surge in chronic diseases, thereby leading to an enhanced demand for advanced drug delivery solutions that can improve patient's quality of life. Enhanced treatment options through nanotechnology are critical in addressing the challenges posed by these illnesses, positioning the industry for sustained growth.

## **Nanotechnology-Based Drug Delivery Market Segment Insights**

### **Nanotechnology-Based Drug Delivery Market Application Insights  **

The Nanotechnology-Based Drug Delivery Market is witnessing notable growth, particularly in its Application segment, which encompasses various medical conditions where nanotechnology plays a vital role in enhancing therapeutic efficacy. By 2023, the overall market was valued at 6.01 USD Billion, with a projected increase to 15.0 USD Billion by 2032, reflecting the increasing reliance on advanced drug delivery systems across multiple healthcare sectors.

Within this segment, [Oral Cancer Treatment](../../../reports/oral-cancer-treatment-market-1820) holds the majority, with a valuation of 2.4 USD Billion in 2023 and expected to reach 5.8 USD Billion by 2032. This dominance is attributed to the effective targeting and delivery of chemotherapy drugs directly to tumor cells, thereby minimizing side effects and improving patient outcomes.

Cardiovascular Diseases also show a significant market presence, holding a value of 1.2 USD Billion in 2023, predicted to grow to 3.0 USD Billion by 2032. The application of nanotechnology in this area allows for improved drug solubility and circulation time essential for managing complex cardiovascular conditions.

Neurological Disorders, valued at 1.0 USD Billion in 2023 and projected at 2.5 USD Billion by 2032, benefit greatly from nanotechnology's potential to cross the blood-brain barrier, facilitating the delivery of therapeutics for diseases such as Alzheimer's and Parkinson's.Infectious Diseases are represented with a market valuation of 1.21 USD Billion in 2023, expected to rise to 2.9 USD Billion by 2032, as the need for effective treatment methods continues to grow amidst rising antibiotic resistance and global health challenges.

Lastly, Autoimmune Disorders, while currently at 0.2 USD Billion in 2023 with a forecast of 0.8 USD Billion in 2032, indicate a growing area for nanotechnology-driven treatments, providing targeted approaches to modulating immune responses. Market trends suggest that the increase in chronic and complex diseases alongside advancements in nanotechnology research will drive further growth across these applications, allowing for tailored therapies and improved patient outcomes while addressing challenges such as regulatory hurdles and the cost of development.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Nanotechnology-Based Drug Delivery Market Nanoparticle Type Insights  **

Within this market, the Nanoparticle Type segment plays a crucial role, comprising various key components. Liposomes are recognized for their ability to encapsulate drugs and improve bioavailability, making them a dominant force in enhancing therapeutic efficacy.

Polymeric Nanoparticles are also pivotal, offering tailored release profiles that enhance drug stability and patient compliance. Dendrimers provide a versatile platform due to their branched structures, facilitating targeted drug delivery. Solid Lipid Nanoparticles exhibit advantages in sustained release and drug protection, contributing to their growing adoption in this market.

Additionally, Nanocrystals are notable for their increased solubility and absorption properties. As such, the segmentation within the Nanotechnology-Based Drug Delivery Market highlights a diverse array of innovations that not only cater to different therapeutic needs but also address various challenges in drug delivery systems. The ongoing trends in nanotechnology are expected to unlock new opportunities for advancements in targeted therapies and personalized medicine.

### **Nanotechnology-Based Drug Delivery Market Route of Administration Insights  **

** **In 2023, the Nanotechnology-Based Drug Delivery Market was valued at 6.01 USD Billion, demonstrating robust potential within the Route of Administration segment. This market encompasses a diverse array of delivery methods, including intravenous, oral, topical, inhalation, and transdermal routes. Intravenous administration is often preferred for its rapid onset of action and precise dosing, which caters to critical medical needs. The oral route continues to be significant due to its non-invasive nature and patient compliance. 

Topical applications are on the rise, given their convenience and localized effect, while inhalation methods are gaining traction, particularly for respiratory diseases, allowing for targeted delivery.Transdermal systems are also noteworthy, as they provide controlled release and sustained therapeutic effects.

As the market evolves, trends show increasing demand for these delivery methods driven by innovations in nanotechnology, improvements in drug bioavailability, and lifestyle changes in patients seeking effective treatments. With the Nanotechnology-Based Drug Delivery Market expected to grow significantly, these avenues present substantial opportunities and challenges alike, reshaping the future of medication delivery systems and impacting Nanotechnology-Based Drug Delivery Market data and statistics.

### **Nanotechnology-Based Drug Delivery Market End-Use Insights  **

The Nanotechnology-Based Drug Delivery Market has demonstrated significant potential across various end-use sectors like hospitals, pharmaceutical companies, research institutions, and home care settings. As of 2023, the market was valued at approximately 6.01 billion USD, highlighting its growing relevance in healthcare. Hospitals play a crucial role in this market due to the increased demand for advanced treatment options, providing critical infrastructure for implementing nanotechnology solutions in patient care. Pharmaceutical companies are integral, as they invest heavily in the development of nanomedicine to enhance drug efficacy and safety.

Research institutions significantly contribute through innovative studies that propel technological advancements in drug delivery mechanisms that improve therapeutic outcomes. Home care settings are gaining traction, reflecting a trend toward personalized medicine where patients benefit from sophisticated drug delivery methods within their homes.

The increasing adoption of these technologies across these segments is driven by the rising prevalence of chronic diseases and the need for more efficient and targeted therapies, making the Nanotechnology-Based Drug Delivery Market a dynamic and evolving landscape in the industry.

### **Nanotechnology-Based Drug Delivery Market Regional Insights  **

The Nanotechnology-Based Drug Delivery Market has shown significant regional variation in its valuation, with North America leading the market at 2.55 USD Billion in 2023, projected to rise to 6.15 USD Billion by 2032, demonstrating its major role in the market's dynamics.

Europe follows as a key player valued at 1.8 USD Billion in 2023, expected to reach 4.45 USD Billion in 2032, signifying its growing investment in advanced drug delivery systems. The APAC region, with a market value of 1.3 USD Billion in 2023, is projected to grow to 3.2 USD Billion, making it an important area of development fueled by rising healthcare access and a growing population.

Meanwhile, South America and the MEA regions represent smaller shares with valuations of 0.25 USD Billion and 0.11 USD Billion in 2023, respectively, yet both regions show potential for market growth due to increasing healthcare demands and technological advancements. Collectively, these figures reflect the growing significance of the Nanotechnology-Based Drug Delivery Market across various global regions, driven by innovations, rising healthcare expenditure, and the need for effective drug delivery systems.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Nanotechnology-Based Drug Delivery Market Key Players and Competitive Insights**

The Nanotechnology-Based Drug Delivery Market is experiencing significant growth fueled by advancements in nanotechnology that enable precise delivery of therapeutic agents. As this market evolves, competition intensifies among key players who leverage innovations to enhance the efficacy and safety of drug delivery systems. Companies are increasingly investing in research and development to create specialized nanoparticles, smart drug delivery systems, and targeting mechanisms that improve patient outcomes. The landscape is characterized by collaborations, partnerships, mergers, and acquisitions as firms seek to broaden their portfolios and strengthen their market positions. 

Regulatory advancements and increased funding in nanotechnology research are anticipated to propel market growth further, shaping a dynamic competitive environment.Sanofi has established a strong presence in the Nanotechnology-Based Drug Delivery Market through its focused approach to innovative drug delivery systems.

The company is recognized for its robust research and development capabilities, enabling it to create advanced nanocarriers that enhance the solubility and bioavailability of poorly soluble drugs. Sanofi's commitment to developing targeted therapies has positioned it favorably in the market, allowing it to effectively address complex medical conditions and cultivate a loyal customer base. 

The company's strategic collaborations with academic institutions and technology firms have further augmented its capabilities, ensuring a continuous pipeline of innovative solutions. Moreover, Sanofi's strong global distribution network and established healthcare relationships underscore its competitive strength, providing the company with a significant advantage in bringing its nanotechnology solutions to a wider audience.Merck and Co. are making substantial strides in the Nanotechnology-Based Drug Delivery Market, demonstrating a commitment to integrating cutting-edge nanotechnology into its pharmaceutical offerings. 

The company holds a reputation for its strong research foundation, leveraging a wealth of knowledge in chemistry and biology to develop novel nanoparticle formulations that enhance drug delivery and therapeutic efficacy. Merck and Co is also recognized for its ability to navigate complex regulatory landscapes, ensuring its products not only meet safety and efficacy standards but also gain timely market access. The firm actively engages in partnerships with technology innovators to foster advancements in drug delivery systems, enhancing its product offerings. 

With a focus on life sciences and biotechnology, Merck and Co's sustained investment in nanotechnology research serves to strengthen its competitive positioning, allowing it to deliver pioneering solutions to meet the evolving demands of patients and healthcare providers alike.

### **Key Companies in the Nanotechnology-Based Drug Delivery Market Include**

- **[Sanofi](https://www.sanofi.com/en/magazine/our-science/nanobody-technology-platform)**
- Merck and  Co
- AstraZeneca
- AbbVie
- Celgene
- Bristol-Myers Squibb
- Takeda Pharmaceutical
- Gilead Sciences
- Teva Pharmaceutical
- Roche
- Eli Lilly
- Johnson and  Johnson
- Pfizer
- Novartis
- Amgen

## Nanotechnology Based Drug Delivery Industry Developments

- **Q2 2024: NanoCarrier Announces FDA Approval of Nanoparticle-Based Chemotherapy Formulation for Breast Cancer** NanoCarrier Co., Ltd. received FDA approval for its nanotechnology-based drug delivery formulation, NC-6004, for the treatment of metastatic breast cancer, marking a significant regulatory milestone for nanomedicine in oncology.
- **Q2 2024: CureVac and Acuitas Therapeutics Announce Strategic Partnership to Develop Nanoparticle-Based mRNA Drug Delivery Platforms** CureVac N.V. and Acuitas Therapeutics entered a multi-year partnership to co-develop and commercialize lipid nanoparticle (LNP) drug delivery systems for mRNA therapeutics, expanding both companies' nanotechnology portfolios.
- **Q3 2024: Nanospectra Biosciences Raises $30 Million Series C to Advance Nano-Based Drug Delivery for Solid Tumors** Nanospectra Biosciences, Inc. secured $30 million in Series C funding to accelerate clinical development of its nanoshell-based drug delivery platform targeting solid tumors.
- **Q3 2024: AstraZeneca Opens New Nanomedicine Manufacturing Facility in Sweden** AstraZeneca inaugurated a state-of-the-art manufacturing facility in Gothenburg dedicated to the production of nanotechnology-based drug delivery systems, aiming to scale up commercial supply for global markets.
- **Q4 2024: Bristol Myers Squibb and Nanoform Enter Collaboration to Enhance Drug Solubility Using Nanotechnology** Bristol Myers Squibb and Nanoform Finland Plc announced a collaboration to apply Nanoform’s nanoparticle engineering technology to improve the solubility and bioavailability of select BMS pipeline compounds.
- **Q4 2024: Moderna Acquires Nanomedicine Startup Precision NanoSystems for $250 Million** Moderna, Inc. acquired Precision NanoSystems, a developer of nanotechnology-based drug delivery platforms, to strengthen its capabilities in RNA therapeutics and expand its pipeline.
- **Q1 2025: Evonik Launches New Lipid Nanoparticle (LNP) Platform for mRNA Drug Delivery** Evonik Industries AG launched a new lipid nanoparticle platform designed to improve the delivery and stability of mRNA-based therapeutics, targeting both pharmaceutical partners and in-house development.
- **Q1 2025: Sorrento Therapeutics Receives IND Clearance for Nanoparticle-Delivered siRNA Therapy in Pancreatic Cancer** Sorrento Therapeutics, Inc. received FDA Investigational New Drug (IND) clearance to begin clinical trials of its siRNA therapy delivered via proprietary nanoparticles for advanced pancreatic cancer.
- **Q2 2025: Pfizer and BioNTech Expand Nanoparticle Drug Delivery Collaboration to Include Autoimmune Diseases** Pfizer Inc. and BioNTech SE expanded their existing partnership to develop nanoparticle-based drug delivery systems for a new portfolio of autoimmune disease therapies.
- **Q2 2025: Arcturus Therapeutics Announces $100 Million Public Offering to Fund Nanotechnology-Based mRNA Programs** Arcturus Therapeutics Holdings Inc. completed a $100 million public offering to support the advancement of its proprietary nanotechnology-based mRNA drug delivery programs.
- **Q3 2025: Johnson & Johnson Launches First Commercial Nanoparticle-Enabled Oral Drug for Rheumatoid Arthritis** Johnson & Johnson launched the first commercially available oral drug for rheumatoid arthritis utilizing a proprietary nanoparticle-based delivery system to enhance absorption and efficacy.
- **Q3 2025: Merck KGaA Appoints New Head of Nanomedicine Division to Accelerate Drug Delivery Innovation** Merck KGaA announced the appointment of Dr. Anna Schmidt as the new Head of its Nanomedicine Division, tasked with driving innovation and commercialization of nanotechnology-based drug delivery solutions.

## **Nanotechnology-Based Drug Delivery Market Segmentation Insights**

### **Nanotechnology-Based Drug Delivery Market Application Outlook**

- Cancer Treatment
- Cardiovascular Diseases
- Neurological Disorders
- Infectious Diseases
- Autoimmune Disorders

### **Nanotechnology-Based Drug Delivery Market Nanoparticle Type Outlook**

- Liposomes
- Polymeric Nanoparticles
- Dendrimers
- Solid Lipid Nanoparticles
- Nanocrystals

### **Nanotechnology-Based Drug Delivery Market Route of Administration Outlook**

- Intravenous
- Oral
- Topical
- Inhalation
- Transdermal

### **Nanotechnology-Based Drug Delivery Market End-Use Outlook**

- Hospitals
- Pharmaceutical Companies
- Research Institutions
- Home Care Settings

### **Nanotechnology-Based Drug Delivery Market Regional Outlook**

- North America
- Europe
- South America
- Asia-Pacific
- Middle East and Africa

## Market Drivers

### 慢性疾病的日益普遍

慢性疾病（如癌症、糖尿病和心血管疾病）的发病率上升是纳米技术药物递送市场的主要驱动因素。随着这些疾病的日益普遍，对创新治疗方式的需求也在加剧。纳米技术提供了靶向药物递送的潜力，这可以提高治疗效果，同时减少副作用。根据最近的估计，慢性疾病约占全球所有死亡人数的70%，这突显了对有效治疗方案的迫切需求。这一趋势可能会推动对纳米技术研究和开发的投资，从而扩大基于纳米技术的药物递送系统的市场。

### 纳米技术的技术进步

纳米技术的技术创新正在推动基于纳米技术的药物递送市场向前发展。最近在纳米载体系统方面的进展，如脂质体、树枝状聚合物和聚合物纳米颗粒，增强了药物递送的效率和有效性。这些创新提高了生物利用度和治疗药物的控制释放，这对于治疗复杂疾病至关重要。预计纳米载体市场在未来几年将以超过10%的年复合增长率（CAGR）增长，反映出对先进药物递送技术的日益依赖。随着研究的不断发展，纳米技术在药物递送中的潜在应用可能会扩大，进一步推动市场增长。

### 纳米技术研究投资增加

对纳米技术研究的投资激增是纳米技术药物递送市场的重要催化剂。各国政府和私营实体越来越认识到纳米技术在革新医疗保健方面的潜力。用于研究计划的资金显著增加，数十亿资金被分配用于探索新型药物递送系统。这种财政支持对于促进创新和加速新型纳米技术疗法的发展至关重要。因此，预计市场将见证显著增长，预测到2027年对纳米技术的投资可能超过1000亿美元。这一资金涌入可能会增强纳米技术在药物递送中的能力和应用。

### 纳米技术创新的监管支持

支持纳米技术产品开发和商业化的监管框架对纳米技术药物递送市场至关重要。随着监管机构为药品中纳米材料的安全有效使用制定指导方针，市场准入的路径变得更加清晰。这种监管支持不仅促进了创新，还增强了投资者和利益相关者的信心。最近旨在简化纳米技术疗法审批流程的举措表明了一个有利的监管环境。随着这些框架的不断发展，预计将促进纳米技术药物递送市场的增长，可能导致更强大的创新疗法管道。

### 对个性化医疗的需求日益增长

个性化医疗的转变正在显著影响基于纳米技术的药物递送市场。随着医疗保健逐渐摆脱一刀切的方法，针对个体患者特征量身定制的药物递送系统的需求日益增加。纳米技术促进了根据遗传、环境和生活方式因素调整的定制疗法的发展。这个趋势得到了支持，个性化医疗市场预计到2025年将达到2.5万亿美元，表明其强劲的增长轨迹。因此，纳米技术在药物递送系统中的整合预计将在满足个性化医疗需求方面发挥关键作用。

## Future Outlook

基于纳米技术的药物递送市场预计将在2024年至2035年间以10.72%的年均增长率增长，推动因素包括靶向疗法的进步和对个性化医疗需求的增加。

**New opportunities:**

- 用于实时药物监测的智能纳米载体的开发 与生物技术公司合作开发创新药物配方 进入新兴市场，提供量身定制的递送解决方案

到2035年，市场预计将会强劲，受到创新和战略合作伙伴关系的推动。

## Segment Insights

### 按应用：癌症治疗（最大）与心血管疾病（增长最快）

基于纳米技术的药物递送市场在各个治疗领域的应用中显著形成。其中，癌症治疗占据了最大的份额，反映出在癌症管理的靶向治疗方面的重大关注和投资。相反，心血管疾病正迅速成为增长最快的细分市场，这得益于心脏相关疾病的日益普遍以及对能够提高药物递送效率和减少副作用的创新治疗的需求。因此，市场中既有成熟的应用，也有新兴的应用之间存在着动态的相互作用。

癌症治疗：主导与心血管疾病：新兴

癌症治疗是基于纳米技术的药物递送市场中的一个主导应用，因为它具有靶向治疗和个性化医疗的潜力。能够将药物特定地递送到癌细胞，同时最小化对健康组织的影响，从而增强治疗效果。另一方面，心血管疾病代表了一个新兴领域，其特点是技术迅速进步和对有效疗法的日益增长的需求。纳米技术的整合允许改善药物吸收和持续释放，使其在治疗各种心血管疾病时特别有利。随着医疗系统越来越多地采用这些创新技术，这两个领域都可能会见证显著的进展，癌症治疗将继续领先，而心血管疾病则迅速追赶。

### 按纳米颗粒类型：脂质体（最大）与聚合物纳米颗粒（增长最快）

在基于纳米技术的药物递送市场中，脂质体占据了重要份额，主要由于其多功能性和能够包封广泛的治疗剂。这一主导地位也得到了其在各种药物配方中已建立应用的支持，使其在市场上具有优势。相比之下，聚合物纳米颗粒已成为增长最快的细分市场，受到聚合物化学创新的推动，并且具有靶向药物递送的潜力，从而吸引了越来越多的研发投资。

脂质体（主导）与聚合物纳米颗粒（新兴）

脂质体因其增强药物溶解度和生物利用度的能力而备受推崇，使其在基于纳米技术的药物递送市场中占据主导地位。它们的生物相容性以及包封亲水性和疏水性药物的能力使其在临床和研究环境中都受到欢迎。另一方面，聚合物纳米颗粒作为一种新兴技术，因其可定制的特性和提供药物控制释放的能力而迅速获得关注。它们适应包封各种治疗剂的能力使其在未来增长中具有良好的前景，特别是在癌症等复杂疾病中，精准医疗的需求日益增加。

### 按给药途径：静脉注射（最大）与吸入（增长最快）

纳米技术药物递送市场中的给药途径部分，其市场份额因不同方法而异。静脉给药仍然是最大的细分市场，因为它在提供即时治疗效果方面的有效性，特别是对于需要精确剂量的复杂分子。口服和局部给药途径也占有重要份额，符合患者的偏好和使用便利性，而透皮和吸入方法由于其创新提高了有效性和便利性，正在逐渐崭露头角。给药途径部分的增长趋势表明，个性化医疗和靶向治疗正朝着强劲的方向发展。对非侵入性技术的需求不断增加，推动了口服和透皮递送系统的增长，而吸入方法由于纳米载体系统的技术创新正在迅速发展。此外，慢性疾病的日益普遍促使对更有效的药物递送方法的研究，进一步推动了吸入和透皮途径的市场发展。

静脉注射（主导）与经皮给药（新兴）

静脉药物输送在基于纳米技术的药物输送市场中仍然占据主导地位，因为它具有无与伦比的快速全身吸收能力和对药物剂量的精确控制。它特别适用于治疗需要快速治疗效果的严重疾病。相比之下，透皮输送作为一个重要的市场参与者正在崛起，提供非侵入性的替代方案，增强患者的依从性。这种方法利用纳米技术改善皮肤的渗透性，允许活性成分在较长时间内进行控制释放。随着纳米载体系统的创新不断发展，透皮途径在输送各种治疗药物方面变得越来越有能力，使其在日益关注以患者为中心的解决方案的市场中成为一种有前景的方法。

### 按最终用途：医院（最大）与制药公司（增长最快）

在基于纳米技术的药物递送市场中，医院是最大的终端使用细分市场，由于广泛采用先进的药物递送系统以提高治疗效果，医院占据了显著的市场份额。制药公司紧随其后，利用纳米技术开发创新药物，提供改善的生物利用度和靶向递送能力。研究机构和居家护理环境的市场份额较小，但在市场中发挥着至关重要的作用，通过促进研究和提供结合纳米技术的患者管理解决方案。

医院（主导）与制药公司（新兴）

医院在基于纳米技术的药物递送市场中占据主导地位，推动这一市场发展的原因是对先进治疗方案和精准医学的需求。它们的基础设施使得纳米技术能够在各种治疗中得到整合，从而提高患者的治疗效果和运营效率。相比之下，制药公司通过创新药物配方，利用纳米技术实现靶向递送和减少副作用，正在成为一个充满活力的力量。对个性化医学的日益关注正在推动这一细分市场的增长，因为这些公司正在投资于研究和合作，旨在开发满足特定患者需求的基于纳米技术的疗法。

## Regional Market Share Analysis

基于纳米技术的药物递送市场在估值上显示出显著的区域差异，北美在2023年以25.5亿美元领先市场，预计到2032年将上升至61.5亿美元，展示了其在市场动态中的重要角色。

欧洲作为关键参与者，2023年估值为18亿美元，预计到2032年将达到44.5亿美元，标志着其在先进药物递送系统上的投资不断增长。亚太地区在2023年的市场价值为13亿美元，预计将增长至32亿美元，成为一个重要的发展领域，受到医疗保健可及性提高和人口增长的推动。

与此同时，南美和中东及非洲地区的市场份额较小，2023年的估值分别为2.5亿美元和1.1亿美元，但由于医疗保健需求增加和技术进步，这两个地区都显示出市场增长的潜力。这些数据共同反映了基于纳米技术的药物递送市场在全球各个地区日益重要的意义，受到创新、医疗保健支出增加和有效药物递送系统需求的推动。

来源：初步研究，二次研究，_市场研究未来_数据库和分析师评审

## Competitive Benchmarking

基于纳米技术的药物递送市场正在经历显著增长，这得益于纳米技术的进步，使得治疗药物的精准递送成为可能。随着市场的发展，主要参与者之间的竞争加剧，他们利用创新来提高药物递送系统的有效性和安全性。公司们越来越多地投资于研发，以创造专门的纳米颗粒、智能药物递送系统和靶向机制，从而改善患者的治疗效果。市场的特点是合作、伙伴关系、并购等，企业寻求扩大其产品组合并增强市场地位。

预计监管进展和对纳米技术研究的资金增加将进一步推动市场增长，塑造一个动态的竞争环境。赛诺菲通过其对创新药物递送系统的专注方法，在基于纳米技术的药物递送市场中建立了强大的存在。

该公司因其强大的研发能力而受到认可，使其能够创造先进的纳米载体，增强难溶药物的溶解度和生物利用度。赛诺菲致力于开发靶向疗法，使其在市场上处于有利地位，能够有效应对复杂的医疗状况并培养忠实的客户群。

该公司与学术机构和技术公司的战略合作进一步增强了其能力，确保了创新解决方案的持续供应。此外，赛诺菲强大的全球分销网络和建立的医疗关系突显了其竞争优势，使公司能够将其纳米技术解决方案带给更广泛的受众。默克公司在基于纳米技术的药物递送市场上取得了重大进展，展现了将尖端纳米技术融入其制药产品的承诺。

该公司以其强大的研究基础而闻名，利用丰富的化学和生物学知识开发新型纳米颗粒配方，以增强药物递送和治疗效果。默克公司还因其能够驾驭复杂的监管环境而受到认可，确保其产品不仅符合安全和有效性标准，还能及时进入市场。该公司积极与技术创新者建立合作关系，以促进药物递送系统的进步，增强其产品供应。

专注于生命科学和生物技术，默克公司在纳米技术研究上的持续投资有助于加强其竞争地位，使其能够提供开创性的解决方案，以满足患者和医疗提供者不断变化的需求。

## Recent News & Developments

- **2024年第二季度：NanoCarrier宣布纳米颗粒化疗配方获得FDA批准用于乳腺癌** NanoCarrier有限公司获得FDA批准，其基于纳米技术的药物递送配方NC-6004用于治疗转移性乳腺癌，标志着纳米医学在肿瘤学领域的重要监管里程碑。
- **2024年第二季度：CureVac与Acuitas Therapeutics宣布战略合作开发基于纳米颗粒的mRNA药物递送平台** CureVac N.V.与Acuitas Therapeutics达成多年合作，共同开发和商业化脂质纳米颗粒（LNP）药物递送系统，扩展两家公司在纳米技术领域的产品组合。
- **2024年第三季度：Nanospectra Biosciences筹集3000万美元C轮融资以推进针对实体肿瘤的纳米药物递送** Nanospectra Biosciences, Inc.获得3000万美元C轮融资，以加速其针对实体肿瘤的纳米壳药物递送平台的临床开发。
- **2024年第三季度：阿斯利康在瑞典开设新的纳米医学制造设施** 阿斯利康在哥德堡启用了一个最先进的制造设施，专注于生产基于纳米技术的药物递送系统，旨在扩大全球市场的商业供应。
- **2024年第四季度：百时美施贵宝与Nanoform达成合作以利用纳米技术提高药物溶解度** 百时美施贵宝与Nanoform Finland Plc宣布合作，应用Nanoform的纳米颗粒工程技术以改善部分BMS管线化合物的溶解度和生物利用度。
- **2024年第四季度：Moderna以2.5亿美元收购纳米医学初创公司Precision NanoSystems** Moderna, Inc.收购了纳米技术药物递送平台开发商Precision NanoSystems，以增强其在RNA治疗领域的能力并扩展其产品管线。
- **2025年第一季度：Evonik推出新的脂质纳米颗粒（LNP）平台用于mRNA药物递送** Evonik Industries AG推出了一种新的脂质纳米颗粒平台，旨在改善mRNA基础治疗的递送和稳定性，面向制药合作伙伴和内部开发。
- **2025年第一季度：Sorrento Therapeutics获得FDA对纳米颗粒递送的siRNA疗法在胰腺癌中的IND批准** Sorrento Therapeutics, Inc.获得FDA的研究新药（IND）批准，开始其通过专有纳米颗粒递送的siRNA疗法在晚期胰腺癌中的临床试验。
- **2025年第二季度：辉瑞与BioNTech扩大纳米颗粒药物递送合作以涵盖自身免疫疾病** 辉瑞公司与BioNTech SE扩大了现有合作，开发基于纳米颗粒的药物递送系统，用于新的自身免疫疾病治疗组合。
- **2025年第二季度：Arcturus Therapeutics宣布1亿美元公开募股以资助基于纳米技术的mRNA项目** Arcturus Therapeutics Holdings Inc.完成了1亿美元的公开募股，以支持其专有基于纳米技术的mRNA药物递送项目的推进。
- **2025年第三季度：强生推出首个商业化的纳米颗粒增强口服药物用于类风湿性关节炎** 强生推出了首个商业化的口服药物，利用专有的基于纳米颗粒的递送系统来增强吸收和疗效，针对类风湿性关节炎。
- **2025年第三季度：默克KGaA任命新纳米医学部门负责人以加速药物递送创新** 默克KGaA宣布任命安娜·施密特博士为新任纳米医学部门负责人，负责推动基于纳米技术的药物递送解决方案的创新和商业化。

## Report Scope

| 2024年市场规模 | 73.7（十亿美元） |
| --- | --- |
| 2025年市场规模 | 81.6（十亿美元） |
| 2035年市场规模 | 225.9（十亿美元） |
| 复合年增长率（CAGR） | 10.72%（2024 - 2035） |
| 报告覆盖范围 | 收入预测、竞争格局、增长因素和趋势 |
| 基准年 | 2024 |
| 市场预测期 | 2025 - 2035 |
| 历史数据 | 2019 - 2024 |
| 市场预测单位 | 十亿美元 |
| 主要公司简介 | 市场分析进行中 |
| 覆盖的细分市场 | 市场细分分析进行中 |
| 主要市场机会 | 针对性疗法的进步增强了纳米技术药物递送市场的增长潜力。 |
| 主要市场动态 | 对针对性疗法的需求上升推动了基于纳米技术的药物递送系统的创新，并提高了治疗效果。 |
| 覆盖的国家 | 北美、欧洲、亚太、南美、中东和非洲 |

## Frequently Asked Questions

**Q: 纳米技术药物递送市场的当前估值是多少？**
A: 截至2024年，市场估值为73.7亿美元。

**Q: 到2035年，基于纳米技术的药物递送市场的预计市场规模是多少？**
A: 预计到2035年，市场将达到225.9亿美元。

**Q: 在预测期内，基于纳米技术的药物递送市场的预期CAGR是多少？**
A: 预计市场在2025年至2035年的年均增长率（CAGR）为10.72%。

**Q: 预计哪个应用领域在市场上将实现最高增长？**
A: 预计癌症治疗市场将从2024年的18.5亿美元增长到2035年的56.7亿美元。

**Q: 在基于纳米技术的药物递送市场中，领先的纳米颗粒类型有哪些？**
A: 聚合物纳米颗粒和脂质体是领先的类型，预计到2035年分别达到67.3亿美元和45.6亿美元。

**Q: 给药途径如何影响市场动态？**
A: 静脉给药预计将从2024年的18.5亿美元增长到2035年的56.7亿美元，显示其重要性。

**Q: 像安进和辉瑞这样的关键参与者在市场中扮演什么角色？**
A: 像安进和辉瑞这样的关键参与者可能会通过先进的药物递送系统推动创新和市场增长。

**Q: 到2035年，预计哪个最终用途细分市场将主导市场？**
A: 制药公司预计将在最终用途领域中占主导地位，预计从2024年的29.6亿美元增长到2035年的87.8亿美元。

**Q: 哪些趋势正在影响基于纳米技术的药物递送市场的增长？**
A: 慢性疾病的日益普遍和纳米技术的进步正在影响市场增长。

**Q: 神经系统疾病的市场与其他应用相比如何？**
A: 神经系统疾病市场预计将从2024年的11亿美元增长到2035年的33亿美元，反映出显著增长。


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/nanotechnology-based-drug-delivery-market-34011*